Search
Ensifentrine
go.drugbank.com/drugs/DB16157ApprovedInvestigationalEnsifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. … [L50903] On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) in adults, which allows the drug to be
Synonyms: N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREA, UREA, N-(2-(6,7-DIHYDRO-9,10-DIMETHOXY-4-OXO-2-((2,4,6-TRIMETHYLPHENYL)IMINO)-2H-PYRIMIDO(6,1-A)ISOQUINOLIN-3(4H)-YL)ETHYL)-Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalValbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's … [A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively.
Phensuximide
go.drugbank.com/drugs/DB00832ApprovedIt suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. … Phensuximide is a member of the succinimide class with anticonvulsant properties.
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSalsalate is a nonsteroidal anti-inflammatory agent for oral administration. … Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
Glycyrrhiza glabra
go.drugbank.com/drugs/DB14312ApprovedInvestigationalWithdrawnGlycyrrhiza glabra is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Vita-lax, Ultra-laxSynonyms: Glycyrrhiza Glabra L Rhizome Extract, Glycyrrhizae Radix Et Rhizoma (Glycyrrhiza Glabra)Recombinant stabilized RSV B prefusion F antigen
go.drugbank.com/drugs/DB18714ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Deutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalThis allows less frequent dosing and a lower daily dose with improvement in tolerability [A32043]. … Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease.
Metreleptin
go.drugbank.com/drugs/DB09046ApprovedInvestigationalLipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. … [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized
Synonyms: N-MethionylleptinTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalIn February 2022, tepotinib was approved for use in Europe.[L42200] … [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is
Zotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawnIn the EMA, by 2015 it was under pharmacovigilance studies for the potential treatment of acute renal failure.[L1314] … Zotepine, with the formula (2-chloro-11-(2-dimethyl-amino-ethoxy)-dibenzo thiepin, is a neuroleptic drug. It was designed and synthesized by Fujisawa Pharmaceutical Co Ltd.